港股異動 | 信達生物-B(1801.HK)漲超5%續創新高 下週一起股份簡稱將不再標記“B”
格隆匯6月26日丨信達生物-B(1801.HK)盤中高見61港元續創上市新高,現報60.85港元,漲5.09%,暫成交9514萬港元,最新總市值817億港元。公司6月24日晚間發公告稱,自6月29日(即下週一)起,公司的股份名稱及股份簡稱將不再加上標記“B”。大摩近日發研報指,多種因素將催化信達生物股價表現,包括貝伐單抗仿製藥的獲批等。考慮到其新藥品開發能力及不斷拓展的國際合作,將信達生物列為行業首選,並上調目標價45%至64港元。該行指,由於銷量增長和營銷成本小幅度下降,預期公司今年及明年虧損將有望收窄,並有望於2022年轉虧為盈。此外,公司有望被納入港股通,南向資金料驅動股票需求。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.